Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This would appear that they are in heavy negotiations and are making sure that the terms on royalties with previous licensees remain airtight for at least another 6 1/2 years. Something is up.
Please use the link I provided. There are other segments available on youtube and do a little homework and you will see that these are bar none the most "outside the box" brilliant minds that will change our world as we know it. It is such a perfect fit for our company. I truly believe Dr Moro would be a star, and it would have such an impact on financing and help us find a cure using recaf. We often talked about the need for Dr Moro to have proper media coverage. I personally feel we can make a significant difference in our health care system and save so many lives if the recaf technology was in the right hands.
Just on a humanitarian level alone, I feel he would shock the audience that his discovery isn't front page news. I promise you if Dr Moro actually spoke to an audience of this stature and magnitude we would see the fruit of this over night. I am really hyped about this. It's a perfect platform. He will be in the sweet spot as far as a target audience goes. These people meet with the sole intention of solving the most complex issues we face. As an investor, I would find it inexcusable not to make an attempt to be a guest speaker unless he is not wholeheartedly concerned with the direction of this company.
I was inspired by an HBO special called "The Future We Will Create: Inside the World of TED." I urge everyone to google this and pull it up from youtube. These are the most brilliant minds that get together to solve the world's greatest problems. My wish, if I could have just one, would be to see Dr Moro present his incredible findings to an audience that would embrace this technology and accept the fact that we now have this technology that could end the world suffering from cancer.
I know that a speech from Dr Moro would inspire this community of great minds to see what an impact this could make on humanity.
Please take a look. This would catapult Biocurex to a level Dr Moro never could have dreamed possible. I would love to find out a way to contact the curator of TED and arrange for Dr Moro to share his discovery with people that actually care about the world we live in.
Those of us who read this board or have followed the company for several years have so much pent-up frustration over the pace at which RECAF is being commercialized. We need to see this happen sooner rather than later for so many reasons. Maybe it will touch the right person or organization and we will get a push forward. It is sad that in our own country we are so barraged with beaurocracy that we will have to travel to Europe to get tested with RECAF. I'm sure everyone here would be very interested in having the serum RECAF test on ourself as well as every one of our friends and family.
Because of taking meds to avoid rejection from the organ transplant, it can, but is statistically unlikely to cause a reaction to trigger cancer. Please check with your surgeon if you are concerned. I'm sure you have to feel very blessed with this modern-day miracle. I want to wish only the best.
Why rehash the same news? Is he sending us a message in regards to Europe?
I am impressed. BioCurex has proven to be one of the leanest biotech companies with MEANINGFUL progress. It definitely has the feel as if some news is about to propel us, because there have been buyers not concerned with a few pennies and have hit the asking price at the high on the close. Any news of another deal and we will never see our share price at these levels again. IMO, it's coming. There appears to be signs that Dr Moro is making things happen.
10K out. Anything material?
IMO, someone may know something. Last week, Dr Moro gave me good reasons to trust his methodology in the future of this company. I believe we are in the sweet spot of cancer research, diagnosis, and therapy. I sense that things are brewing at BioCurex and Dr Moro's background in dealing with unforseen obstacles in science is a huge advantage in dealing with all of the challenges and adversities he had to succumb to over the years. He definitely knows how to make lemonade out of lemons. He has restored my faith once again, and apparently I'm not the only one. The hedgefund may finally be on board or may be running out of ammunition to hold back the share price. IMO, in the not so distant future, the pennys that made us excited today will be chump change when investors finally figure out what we have. We may be building momentum and we have to break out above the old 52 week high of 86 cents ( not impossible if we pick up some volume). Today's close was encouraging.
60 cents is the mark they have been trying to us back at and it appears they have 3,500,000 shares in warrants to get the job done. I don't know what they have left in their pocket.
The only difference is that on Monday Dr Moro said they are ready to sell the MANUAL test kits not the automated which should be going to trials in collaboration with Inverness. This is not the rapid test. He stated that he now wants to sell it to research centers to confirm the data.
There USED TO BE a concern over lack of data to substantiate claims. Now after licensing agreements, outside validation, several years of multiple collaborations, patents issued, presentations at scientific meetings, published data in scientific journals, and the addition addition of board members to BioCurex with the highest recognition in the field of cancer. Now we are in a compeltely place.
It would be nice to see Goshen talk about RECAF or vice versa, but Dr Moro is strategically doing research in stealth mode.
Columba, has initiated a collaboration with the Center for Cancer Care in Goshen 1 Fertile region of Egypt occupied by the Israelites.
2 Region, S ancient Palestine, conquered by Joshua.
3 Town of Judah.
--------------------------------------------------------------------------------
Goshen, city, United States
Goshen, city (1990 pop. 23,797), seat of Elkhart co., N Ind., on the Elkhart River; inc. 1868. Goshen is in a farm and dairy region; poultry is also raised and processed., Indiana, for developing and evaluating its RECAF(tm) technology.
The collaboration with Biocurex and the Center for Cancer Care is long term and will consist of three phases: The first one will continue and expand the applications of serum and biopsy tests using RECAF(tm). The second phase will focus on imaging applications using RECAF(tm) to detect the location of cancerous tumors in the body. The third phase includes clinical trials in which RECAF(tm) will be used as a way to specifically deliver therapeutic agents to destroy the cancer cells with minimal damage to normal tissues. The third phase is contingent to the previous development of animal and culture models demonstrating the benefits of RECAF for targeting cancer cells.
I was told they are still collaborating.
This clearly spells out our future estimated revenues.......
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAFTM, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAFTM kits provide proof of concept for the RECAF technology. BOCX has patented and proprietary technology that is leading the way in early cancer detection.
BOCX is currently developing and commercializing cancer diagnostic products based upon their breakthrough RECAFTM cancer marker technology.
A vaccine based on BOCX's proprietary RECAFTM technology that would protect against most types of cancer has a $2B market potential in U.S. alone.
Radioisotope imaging of RECAFTM positive cancer cells can be obtained with standard hospital equipment. Projected as a $1B U.S. market share for BOCX.
$ 2 Billion Dollar market targeted for BOCX's single serum test for the diagnosis of numerous types of cancer. To be launched under the name Serum-RECAFTM. $3 Billion Dollar market share is seen as realistic as BOCX joins the Antibody Therapy arena with very favorable results from preliminary studies based on BOCX's RECAFTM technology. BOCX targets growing market for minimizing or eliminating side effects of cancer chemotherapy, utilizing its RECAFTM antibodies for drug and radioisotope delivery. BOCX is seen as a prime-licensing candidate based on the multitude of clinical uses of BOCX's proprietary RECAF TMtechnology. BOCX has assembled a team of renowned individual scientists and experts under the direction of Dr. Phillip Gold, the most eminent investigator in the cancer marker field. Investigators at BOCX have demonstrated that leukemia can be diagnosed and monitored utilizing BOCX's RECAFTM staining technology. By cleansing patients' bone marrow of cancer cells, need for bone marrow transplants might be eliminated.
BOCX's Histo-RECAFTM, a special cancer detection kit for tissues, has been cleared for sale by the FDA for U.S. markets, with an early projected market potential of $200 million. Histo-RECAFTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.
The way they unexpectedly disseminate news everyone should be content with the amount of shares they are holding before it is too late. The last two press releases came out of left field.
As a long time investor in BioCurex I have to wonder if RECAF would have already been a household name if it were not for the SEC halting trading and pushing us back to the pink sheets for almost 2 years. Without merit they assumed that RECAF was not credible, and because of it I feel we unjustly lost credibility with investors and all of Dr Moro's colleagues. I can't imagine how determined Dr Moro became to vindicate his reputation and his life's work. It has in some ways made him truly aware of how important it is to dot all the i's and cross all the t's before he goes public and makes any new claims. He has in some ways become more savvy and I like that he understands how important it is to protect his discovery with a broad range of patents throughout the world. In retrospect, he was forced to take two steps backwards, but now he has managed to recently take a giant leap forward. This undoubtedly will be our year. It will be worth the wait. The only two things I wish for at this point is to sign another major licensee (probably in negotiations now) and to get rid of the hedgefund (the sole reason why we are trding under a dollar). We now only have a market cap around 25 million dollars. That is astounding considering what we own.
Here is one that will likely be updated....
China Grants BioCurex's RECAF Patent: Largest Population Country In The World Approves Technology
BioCurex Inc. (OTCBB:BOCX) is pleased to announce that a patent for its proprietary RECAF(TM) technology for cancer diagnosis has been approved and granted in the People's Republic of China. The patent covers the technologies used in the Company's Histo-RECAF(TM) and Cryo-RECAF(TM)
That is from Nov 2003.
BioCurex has already been issued patents in Australia and Russia and has patents pending in Canada and Japan and most European countries with pending approvals for diagnostic and therapeutic applications which have a much greater market share potential than already stated.
That is from March 2003
Dr Moro is a busy bee.
Sorry Dog, but most of the time we are here to interact together to share sound ideas, and the dialogue was getting off track. Personally, you can and should do whatever you want with your shares, but I believe most of us go way back and have had a long term outlook on RECAF. This board has given us solice during some turbulent times and it has had a major effect in that it has kept most of us in the game. Yesterday was a well needed shot in the arm, and most of us have come to the same conclusions. This has recently became a slam dunk and given the expansive knowledge Dr Moro has accrued over the past years experimenting with RECAF he knows he can and will find the best and most efficient way to irradicate cancer using RECAF.
Dog, I hope you as well as everyone will continue to benefit from this chatroom. I am guilty of losing it myself, but I will give management a pass as far as future communications. I never realized that Dr Moro's discovery is in a different league compared my other investments when it comes to providing information or updates to shareholders. Dr Moro gave us an explanation why it is so critical not to show your competition what you are doing until it is a done deal. IMO, it won't be long before we get more news.
Dog, you must be high from sniffing your own doodoo. What are these comments?
My money is in the bank of BioCurex and I have taken every dip to add to my position. This is not a stock to flip. I t is an investment. I'm not saying that I didn't have doubts or serious frustration, but last night made complet sense of why we were not given updates.
Dog, please reread my post #12867 so I don't have to bore everyone else here. The hedgefund is giving people money today. Grab it. We are going to see how many shares the hedgefund is willing to part with.
Sorry Dog. There is no way to downplay what just happened. We own the patents to a multibillion dollar discovery. If that doesn't stir up your emotions then you don't how lucky you are to own shares in this company. Maybe it was blind luck you discovered BioCurex, but there are many of us that truly have an understanding of what Dr Moro revealed last night. Reread my post #12867.
This particular area in medicine is like astronomy. Think about the abyss and the enormity of the universe. Well, Dr Moro has discovered what everyone has been searching for. He did not want all of the other scientists that have been searching for the same thing to find out about his discovery until he had collected enough data to back up his claim. Well, yesterday he made it abundantly clear that he has indeed discovered the Holy Grail.
I noticed those morons at the hedgefund are gong to try and hold the share price to 60 cents or less. They will be crying and we'll get the last laugh. Whatever they are thinking Dr Moro does not want any mor dilution, so they are now just throwing money to everyone who wants cheap shares. This is the last chance before we see the major appreciation we were waiting for.
Today is a new day and what change in investor sentiment.
Gold, don't you feel like Dr Moro has answered alot of the mystery behind no shareholder updates? I'm sure it was difficult for him not to say anything about what was going on behind the scenes. We eliminated any serious doubt.
I have been waiting 4 years to get those answers and I couldn't have asked for a better explanation. It was the best scenario I could have hoped for.
WOW! It finally makes sense. I said he was recently in Europe, obviously about the patents, possibly also negotiating.
He was so fed up with Abbott that he waited until his RECAF patents in Europe were a done deal and then he told Abbott now there's a new sheriff in town. He got the leverage to prove that this is viable and will be worth billions, and after Abbott proved useless in providing us any clinical support(which now has come back to haunt them) he wants to get paid, and not with a check for a measly 50 grand.
Read what he is specificly saying.............
In our License agreements, 'granted' patent claims generate a
significantly higher royalty than 'pending' claims for any given country.
I'm not tooting my own horn, but I saw the writing on the wall about getting approval in Europe first.
Dr Moro says alot in this press release that gives me the utmost gratitude and confidence.
This particular statement is the most telling to me as to why no press releases or even a hint as to what he has been up to, especially this statement.............
``It is very important to understand the RECAF technology in detail in order to file patents based on the knowledge thus acquired. Pending approval of our patent, we have delayed publishing results in scientific journals since this would require us to supply extensive information so the studies can be reproduced by other scientists. Publishing certain critical information prior to receiving the approval for our patent would constitute 'prior art' that could interfere with the claim for a patent.'
In essence, any hint of this could have allowed other scientists to work toward a patent (ie Abbott) and stole it. That is why he preferred not to have his work published in any journals until he had the patents to prove it was his discovery.
AWESOME, DR M. I am very impressed.
He also recognizes that he is extending the life of the patents, so we could expect royalties for many more years.
"We are currently writing new patent applications based on the knowledge gained in the past two years. These patents -- which relate to the serum tests, the rapid tests and the RECAF chemistry in general -- should not only add value to BioCurex, but will also extend the patent protection provided by our current patents for the next two decades."
Lastly, he made a comment as if to apologize to shareholders, but gave good reasons for all the mystery and speculation that has literally plagued this stock for almost 4 years.
"We must keep thinking and acting with the long term benefit of the Company in mind; and we are thankful for the understanding and patient support of our shareholders. The efforts are paying off!``
This stock without that hedgefund would be several dollars. I am extremely content with this particular press release it answered most questions we have had over the last few years. He couldn't speak about any of this until it was a done deal. I also think the timing was good, because we now know why HE did what he did with Abbott and it was not the other way around. This good news means alot more today being separated from Thursday's news. We all said it was either a zero or our loterry ticket. Well, I think we just got another number correct and we are getting very close to the jackpot.
Congratulations to everyone who kept the faith.
Even the hedge fund has their limits on where they would sell. IMO, this would be the best possible time to see some good news. If they have have it they should strike now, because if it was mixed in with last weeks pr it would have diminished any of the positives. Dr Moro, do it now if you were holding back!
I thought the idea is to BUY low sell high. Gold your work is well appreciated. You personally have objectively stated facts and that's why you are an important reason why this stock did not see what we all thought would be an overreaction. Great work my friend!
Most investors in Biocurex have enough intelligence to know this is either a zero or a once in a lifetime opportunity. After the ISOBM I have no doubts my patience will more than justify the swings in share price. I urge everyone to keep the faith. We are so close that I would never consider selling.
Sorry Dog. We all know you were strongly convicted to this stock and I was surprised that you weren't buying at these levels.
Our company is in the sweet spot of what current medicine is so hopeful in achieving. We hold the Golden Ticket. Diagnostics, Imaging, and Therapeutics. We will see revenues from all three.
GS, I agree. I have no intentions of selling. I am now more excited that Dr Moro has stuck his head outside the lab and he gave Abbott a dose of who really has the power. He probably is afraid to say he is finalizing another licensee until it is a done deal. Please let it be Quest or Labcorp.
He certainly has no reason to back down from the results obtained and to further validate the outstanding results he is finally giving any naysayers an opportunity to see for themselves.
"We are also finalizing a commercial version of our manual test (Serum-RECAF-M(tm)) which we plan to market for research purposes so that additional supportive data can be accumulated by independent research and clinical labs."
The lightbulb went off and he has finally realized it is ready for the world to see for themselves. It would be a travesty if the entire scientific community in the area of cancer research doesn't accept his offer and come to grips with the fact that someone, somehow has truly found the answer to end alot of unnecessary suffering.
This is the time to alert the media in such a way that we will be brought into the spotlight. He is now challenging the medical community to test RECAF to find a way to refute the evidence that he has actually discovered a single universal cancer marker shown to be present in all types of cancer. I would consider this very big news that should get widespread media coverage. One man is standing up to the entire medical community and saying I dare you to prove me wrong.
When you read the press release again Dr Moro says he is pretty much ready to commercialize the manual recaf test to generate a revenue stream and it is the automated test that will require more due diligence. The manual test has been extemely proficient for quite some time, but he was concentrating on the automated test so hard that he was forgetting that he can sell the manual test now. This is a class 1 device and will not require the PMA (or am I mistaken)? We need to get this into the hands of all academia so they can see for themselves this wasn't contrived data we were presenting.
If Dr Moro knew Abbott was a dud, he was at a crossroads with them, and the future required more money from somewhere, wouldn't it be correct to assume that he asked Inverness for a large upfront payment, and that is how he is paying off the loan? You can see by the Matria deal that they intend to stick by their word when they make an agreement.
My hope is that we partner with Quest or Labcorp.
At some point we need to pair up with the likes of a superstar biotech company like Genentech or Amgen to use our technology or as Dr Moro likes to say "piggyback" onto RECAF to allow their drugs to reach only the cancer cells in order to eliminate the destruction or death to normal/healthy cells.
Once again thanks to everyone's input we have pieced together another puzzle. I am certain in the very near future we will look back and say that we were fortunate to have this forum to discuss all issues at hand amongst our fellow investors, and if it were not for that we would have had misjudged or overreacted causing us to miss out on probably the single best opportunity in our lifetimes.
Fasten your seatbelts and expect alot of turbulence come Monday, but I am certain following that we will make a safe landing and all of our lives will be enriched in many ways.
The worst is behind us. I think Dr Moro rolled out of bed the other morning and finally looked at the calendar and noticed three years had passed and just said this is bull****.
Dr Moro wanted Abbott to go thru all of the requirements to get FDA approval. I feel they were on board until they decided to sell off the diagnostic division. That is when things deteriorated in our relationship. This week they also terminated a multibillion dollar deal with Takeda. They are in limbo. Don't forget we still have Dr Steward Sell on our advisory board that just received the Abbott Award at the 2007 ISOBM meeting for his contributions to cancer research. We are still connected to Abbott. Didn't he announce Dr Moro as the discoverer of the "Miracle Protein"?
We will finish the task at hand and when we do we will come out on top. Because of the previous licensing agreement we were very restricted in what we could say or with whom we could collaborate with. We now have the best chance to control our own destiny and at our pace. I'm not saying it wasn't a blow to his ego. He just finally said enough is enough.
I do feel that the timing of the press release was calculated on behalf of Dr Moro. He wanted to prevent a knee-jerk reaction to the news. Most of us see it for what it is worth. He simply is saying that he has complied with everything Abbott had asked of him and more, so now it's time to show me the money. A critical error will be made if does not follow up with a press release to shareholders. I am hoping he does the right thing, and he will use this opportunity to clear the air of any further speculation. If he proceeds in this manner I wouldn't be surprised to see a spike upward, because this would reenforce that we are looking at a very bright future for this company.
Dr Moro, please don't pass up the chance to regain the faith of your shareholders. As our CEO you have an obligation to explain this to those who do not understand that this will have a positive effect on our future revenues.
Future licensees:
1)Laboratory Corp. of America Holdings(LH)
BUSINESS SUMMARY
Laboratory Corporation of America Holdings, together with its subsidiaries, operates as an independent clinical laboratory company in the United States. The company offers a range of testing services used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease, as well as specialty testing services. Its routine tests include blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, HIV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. Laboratory Corporation's specialty tests and related services comprise viral load testing, and HIV genotyping and phenotyping for infectious diseases; cytogenetic, molecular cytogenetic, biochemical, and molecular genetic tests for diagnostic genetics; oncology testing; clinical trials testing for pharmaceutical companies, which conducts clinical research trials on new drugs; forensic identity testing used in criminal proceedings and parentage evaluation services; allergy testing consisting of a range of allergen testing services, computerized analysis, and treatment program that enables primary care physicians to diagnose and treat various allergic disorders; and occupational testing services, which include urine and blood testing services for the detection of drug and alcohol abuse for private and government customers. The company's customers comprise physicians, hospitals, managed care organizations, governmental agencies, employers, pharmaceutical companies, and other independent clinical laboratories. As of December 31, 2007, it operated 37 primary laboratories and approximately 1,600 patient service centers
2)Quest Diagnostics Inc.(DGX)
BUSINESS SUMMARY
Quest Diagnostics Incorporated, together with its subsidiaries, provides diagnostic testing, information, and services in the United States. The company offers routine tests, including blood chemistries, blood cholesterol levels, complete blood cell counts, urinalyses, pregnancy and other prenatal tests, alcohol and other substance-abuse tests, and allergy tests. It also provides anatomic pathology services, including dermatopathology and other cancer diagnostic testing; and gene-based testing and other esoteric testing. In addition, Quest Diagnostics provides central laboratory testing performed in connection with clinical research trials on new drugs and vaccines; and risk assessment services for the life insurance industry. Further, the company manufactures and markets diagnostic test kits and specialized point-of-care testing for the professional market. Quest Diagnostics offers a range of clinical laboratory testing services to patients, physicians, hospitals, healthcare insurers, employers, governmental institutions, and other commercial clinical laboratories. As of December 31, 2007, it operated a network of approximately 2,100 patient service centers and principal laboratories, as well as approximately 150 smaller laboratories
3)Genomic Health Inc.(GHDX)
BUSINESS SUMMARY
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer in the United States. Its clinical diagnostic tests for cancer enable physicians and patients to make individualized treatment decisions. The company's genomic test, Oncotype DX, is a clinical laboratory test that predicts the likelihood of cancer recurrence, the likelihood of patient survival within 10 years of diagnosis, and the likelihood of chemotherapy benefit. This test is focused on patients with early stage, node negative, or N−, and estrogen receptor positive, or ER+, breast cancer. Genomic Health is in the early development phase of investigating additional genes and gene combinations that may add to the predictive power of Oncotype DX; and in the early development phase for a product to predict the likelihood of recurrence and chemotherapy benefit in N− and ER− breast cancer patients, as well as taxane benefit. In addition, the company has products in various stages of development for other cancers, including colon cancer, prostate cancer, renal cell cancer, non-small cell lung cancer, and melanoma. Further, it is in the early development phase to develop tests to predict the likelihood of response to the EGFR inhibitor class of drugs. Genomic Health has a collaborative agreement with Aventis, Inc. to investigate the ability of gene expression in fixed-paraffin-embedded tissues to predict the likelihood of response to adjuvant chemotherapy, including Taxotere, in patients with early breast cancer and zero to three involved lymph nodes.
4)Becton, Dickinson and Company(BDX)
BUSINESS SUMMARY
The company's BD Diagnostics segment provides products for the safe collection and transport of diagnostic specimens and instruments for analysis, including preanalytical and diagnostic systems comprising integrated systems for specimen collection, a line of safety-engineered blood collection products and systems, plated media, automated blood culturing systems, molecular testing systems for sexually transmitted diseases and healthcare-associated infections, microorganism identification and drug susceptibility systems, liquid-based cytology systems for cervical cancer screening, and rapid diagnostic assays. Its BD Biosciences segment offers fluorescence activated cell sorters and analyzers, cell imaging systems, monoclonal antibodies and kits for performing cell analysis, reagent systems for life sciences research, tools to aid in drug discovery and growth of living cells and tissue, cell culture media supplements for biopharmaceutical manufacturing, and diagnostic assays. Becton, Dickinson and Company serves hospitals, laboratories, clinics, consumers and retail pharmacies, public health agencies, pharmaceutical and biotech companies, healthcare workers, blood banks, patients, physicians' office practices, and academic and government institutions.
5)Roche(RHHBY)
Business Summary
Roche Holding is a pharmaceuticals and a diagnostics company which is based in Switzerland. Co.'s products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Co.'s operations are organized along two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Co.'s Diagnostics Division offers a range of products and services in various fields of medical testing
6)Siemans(SI)Gold's favorite
BUSINESS SUMMARY
Siemens' Medical Solutions business offers diagnostic and therapeutic systems, devices, and consumables; and information technology systems.
20cbocx, I reviewed some of your posts. You above all seem the most pessimistic, so I am calling you out. Even your alias 20cbocx says it all. You would love to see this company fail. You are entitled to your opinion, however, don't you ever dispute that RECAF doesn't provide the most accurate way to diagnose cancer, and the greatest hope for finding a cure. Read your own post:
20cbocx posting.....................
Several people have mentioned the billions that RECAF will save by early detection. Think about the people that are currently receiving those billions. Universities around the country receive billions in grants to do cancer and other research. Doctors, drug companies, hospitals, funeral homes receive billions from cancer patients. These entities are not going to roll over and watch their gravy train dissapear in the sunset. Look what the drug companies did to Drs. Marshall and Warren when they discovered that stomach ulcers were caused by the bacteria H. pylori and could be easily cured with antibiotics. One other thing. Have you noticed that we the tax payers pay for all these grants to universities and individuals to do medical research but when something that has potential is discovered it is patented and a corporation formed that is owned by the researcher. The corporation either licenses the product or sells the corporation. The taxpayer that helped fund the research and doesn't have insurance can't afford the treatment. We see RECAF as something wonderful. Believe me, there are many out there that see RECAF as threat to their financial well being and will fight to stop it's introduction in the market. I am one cynical sob.
Those are your words not mine.